Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar ...

The licensing agreement, which includes a big upfront payment of $650 million and milestone payments of up to $4.95 billion, ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers ...

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping ...

Their shared dedication reflects a broader mission to bring meaningful change to women’s health, offering hope and tangible ...

For instance, solutions like eWizard flag errors, from missing references to inappropriate images or typos. And when ...

Global chipmaker giant NVIDIA kicked off JPM Week with several partnership announcements, most notably a billion dollar partnership with Indianapolis-based Eli Lilly.

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on ...